Combined Radiation-Immunotherapy in locally advanced Bladder Cancer Prospective, single-arm, multicenter Phase-II Study to evaluate Safety and Efficacy of preoperative Radioimmunotherapy followed by radical Cystectomy in locally advanced Bladder Cancer (RACE-IT) - AB 65/18 of AUO

被引：0
|
作者：
Rexer, H. [1 ]
Schmid, S. [2 ]
Merseburger, A. [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Tech Univ Munich, Klin Prufung LKP, Klinikum RDI, Urol Klin & Poliklin, Ismaninger Str 22, D-81675 Munich, Germany
[3] Deutsch Krebsgesell eV, Arbeitsgemeinschaft Urol Onkol, Kuno Fischer Str 8, D-14057 Berlin, Germany
来源：
AKTUELLE UROLOGIE | 2020年 / 51卷 / 02期
关键词：
D O I：
10.1055/a-1017-4964
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 102
页数：2
相关论文
共 40 条
  • [21] Efficacy, safety, and biomarkers of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD) advanced ovarian cancer: A prospective, multicenter, phase II, single-arm NANT study
    Gao, Qing-lei
    Liu, Dan
    Li, Huayi
    Zhang, Wei
    Wang, Ping
    Li, Jundong
    Shan, Wanying
    Liu, Ronghua
    Chen, Gang
    Wu, Mingfu
    Li, Xiao
    Liu, Cheng
    Yin, Rutie
    Zhou, Shengtao
    Li, MaoMao
    He, Shanyang
    Zhao, Guangnian
    Song, Kun
    Hong, Li
    Ma, Ding
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial
    Zheng, Rong
    Wang, Congfei
    Huang, Xiaoxue
    Lin, Qingliang
    Huang, Daxin
    Li, Xiao-Bo
    Huang, Heguang
    Xu, Benhua
    BMJ OPEN, 2020, 10 (11):
  • [23] Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study.
    Ding, Ke-Feng
    Chen, Gong
    Ye, Yao
    Liu, Yue
    Sun, Yanlai
    Gao, Yang
    Zhang, Jingdong
    Wei, Shaozhong
    Li, Cong
    Li, Dandan
    Zhou, Yanbing
    Liu, Mulin
    Zhang, Juan
    Zhang, Lilin
    Kong, Dalu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer
    Driesen, Peter
    Lambrechts, Marc
    Kraaij, Kees
    Soldatenkova, Victoria
    Chouaki, Nadia
    Colinet, Benoit
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (03) : 159 - 168
  • [25] An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).
    Sheng, Xinan
    He, Zhisong
    Han, Weiqing
    Zhou, Ai-Ping
    Luo, Hong
    Shi, Yanxia
    Hu, Changlu
    Liu, Ziling
    Guo, Hongqian
    Yao, Xin
    Shi, Benkang
    Liu, Jiyan
    Ji, Zhigang
    Guo, Jianming
    Hu, Yi
    Yu, Shi Ying
    Yu, Guohua
    Ying, Jianming
    Fang, Jianmin
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Efficacy and safety of sequential neoadjuvant chemotherapy and short-course radiation therapy followed by delayed surgery in locally advanced rectal cancer: a single-arm phase II clinical trial with subgroup analysis between the older and young patients
    Bananzadeh, Alimohammad
    Hafezi, Ali Akbar
    Nguyen, NamPhong
    Omidvari, Shapour
    Mosalaei, Ahmad
    Ahmadloo, Niloofar
    Ansari, Mansour
    Mohammadianpanah, Mohammad
    RADIATION ONCOLOGY JOURNAL, 2021, 39 (04): : 270 - 278
  • [27] Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study
    Chai, J.
    Wang, L.
    Liu, L.
    Liu, B.
    Sun, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S908 - S908
  • [28] Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study
    Chai, Jie
    Wang, Longgang
    Liu, Luguang
    Liu, Bing
    Sun, Dong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinical trial
    Zhang, Peng-Fei
    Chen, Ye
    Li, Wen-Ke
    Luo, Zhu-Mei
    Chen, Ji
    Qian, Kun
    Chen, Xiao-Dong
    Wang, Mo-Jin
    Liu, Ming
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [30] Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study
    Lin, Zhenyu
    Zhang, Peng
    Tao, Kaixiong
    Zhang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1234